Showing results (641-650 of 870) with videos related to

Sort By:
Pageof 87
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 16, 2018
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1bDouglas S Goodin, Anthony T Reder, Anthony L Traboulsee, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 5, 2022
Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlapSilvia Morbelli, Silvia Chiola, Maria Isabella Donegani, et al.
Neurobiology of Aging|July 3, 2022
Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary dataFederico Massa, Steffen Halbgebauer, Lorenzo Barba, et al.
European Radiology Experimental|May 5, 2020
123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodiesMatteo Pardini, Flavio Nobili, Dario Arnaldi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 9, 2019
Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosisJames William L Brown, Azmain Chowdhury, Baris Kanber, et al.
European Journal of Physical and Rehabilitation Medicine|May 14, 2024
Dog-assisted physiotherapy in amyotrophic lateral sclerosis: a randomized controlled pilot studyManuela Vignolo, Riccardo Zuccarino, Romina Truffelli, et al.
Annals of Internal Medicine|February 1, 2003
Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammographyPatricia A Carney, Diana L Miglioretti, Bonnie C Yankaskas, et al.
Epilepsy & Behavior : E&B|August 14, 2018
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective studyJerzy P Szaflarski, Elizabeth Martina Bebin, Gary Cutter, et al.
Multiple Sclerosis and Related Disorders|March 17, 2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosisLana Zhovtis Ryerson, John F Foley, Gilles Defer, et al.
Therapeutic Advances in Neurological Disorders|September 24, 2024
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysisGuillemette de la Borderie, Damien Chimits, Babak Boroojerdi, et al.
Pageof 87